Year All2024202320222021202020192018201720162015201420132012201120102007 02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association Read More 01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook - Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19 - - Next interim OS assessment in Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for lead Menin-MLLr inhibitor, SNDX-5613, expected in 2Q19 - WALTHAM, Read More 12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting - Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias - WALTHAM, Mass. , Dec. 3, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company Read More 11.05.18 Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update - Next assessment of primary endpoint of overall survival in E2112 trial expected in the second quarter of 2019 - - Topline data across ENCORE I/O combinations and IND for Menin-MLLr inhibitor expected during the 1H19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. , Nov. Read More 11.01.18 Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting WALTHAM, Mass. , Nov. 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be featured Read More 10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 WALTHAM, Mass. , Oct. 29, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2018 financial Read More 10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer - Enrollment completed in E2112; PFS not statistically significant; trial continues as planned having passed 3rd interim analysis for OS with additional planned OS analyses every 6 months - - Company to provide details of its registration-enabling trial for entinostat in NSCLC patients whose Read More 09.26.18 Syndax to Present at the 2018 Cantor Global Healthcare Conference WALTHAM, Mass. , Sept. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 09.25.18 Syndax Announces Changes to its Board of Directors - Jennifer Jarrett and William Meury appointed to Board of Directors - - Luke Evnin, Ph.D., and Henry Chen resign as active members - WALTHAM, Mass. , Sept. 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical Read More 09.24.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer - Updated biomarker analyses continue to support prior observation of enhanced clinical benefit in subpopulation of patients with elevated baseline levels of peripheral classical blood monocytes; 5.3 month PFS and 21% ORR observed in subpopulation - - Company provides update on timeline for E2112 Read More 09.05.18 Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer WALTHAM, Mass. , Sept. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the PD-(L)1 refractory non-small cell lung Read More 08.28.18 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in Read More
02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association Read More
01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook - Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19 - - Next interim OS assessment in Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for lead Menin-MLLr inhibitor, SNDX-5613, expected in 2Q19 - WALTHAM, Read More
12.03.18 Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting - Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias - WALTHAM, Mass. , Dec. 3, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company Read More
11.05.18 Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update - Next assessment of primary endpoint of overall survival in E2112 trial expected in the second quarter of 2019 - - Topline data across ENCORE I/O combinations and IND for Menin-MLLr inhibitor expected during the 1H19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. , Nov. Read More
11.01.18 Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting WALTHAM, Mass. , Nov. 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be featured Read More
10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 WALTHAM, Mass. , Oct. 29, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2018 financial Read More
10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer - Enrollment completed in E2112; PFS not statistically significant; trial continues as planned having passed 3rd interim analysis for OS with additional planned OS analyses every 6 months - - Company to provide details of its registration-enabling trial for entinostat in NSCLC patients whose Read More
09.26.18 Syndax to Present at the 2018 Cantor Global Healthcare Conference WALTHAM, Mass. , Sept. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
09.25.18 Syndax Announces Changes to its Board of Directors - Jennifer Jarrett and William Meury appointed to Board of Directors - - Luke Evnin, Ph.D., and Henry Chen resign as active members - WALTHAM, Mass. , Sept. 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical Read More
09.24.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer - Updated biomarker analyses continue to support prior observation of enhanced clinical benefit in subpopulation of patients with elevated baseline levels of peripheral classical blood monocytes; 5.3 month PFS and 21% ORR observed in subpopulation - - Company provides update on timeline for E2112 Read More
09.05.18 Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer WALTHAM, Mass. , Sept. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the PD-(L)1 refractory non-small cell lung Read More
08.28.18 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in Read More